Azur sues Barr over generic FazaClo

NEW YORK Ireland-based Azur Pharma has filed a lawsuit against Barr Pharmaceuticals over Barr’s application to the Food and Drug Administration for the approval of a generic version of the antipsychotic drug FazaClo.

In the lawsuit, filed Thursday in federal court in Wilmington, Del., Azur and partner Cima Labs allege that Barr’s approval application infringes their two patents for FazaClo, known generically as Clozapine. The patents expire in 2018.

FazaClo had sales of $34 million over the 12 months ending in June, according to IMS Health data.